1. Home
  2. OPRX vs LUCD Comparison

OPRX vs LUCD Comparison

Compare OPRX & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OptimizeRx Corporation

OPRX

OptimizeRx Corporation

N/A

Current Price

$7.68

Market Cap

167.1M

ML Signal

N/A

Logo Lucid Diagnostics Inc.

LUCD

Lucid Diagnostics Inc.

N/A

Current Price

$0.47

Market Cap

192.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OPRX
LUCD
Founded
2006
2018
Country
United States
United States
Employees
105
N/A
Industry
Business Services
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
167.1M
192.9M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
OPRX
LUCD
Price
$7.68
$0.47
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
4
Target Price
★ $12.30
$4.50
AVG Volume (30 Days)
181.3K
★ 7.8M
Earning Date
11-11-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 124.55
16.67
EPS
★ N/A
N/A
Revenue
★ $109,429,000.00
$4,346,000.00
Revenue This Year
N/A
$34.40
Revenue Next Year
$8.01
$191.30
P/E Ratio
★ N/A
N/A
Revenue Growth
18.78
★ 79.00
52 Week Low
$4.54
$0.30
52 Week High
$15.59
$1.63

Technical Indicators

Market Signals
Indicator
OPRX
LUCD
Relative Strength Index (RSI) 37.22 49.25
Support Level $7.23 $0.30
Resistance Level $8.30 $0.48
Average True Range (ATR) 0.69 0.05
MACD -0.19 0.02
Stochastic Oscillator 38.21 56.12

Price Performance

Historical Comparison
OPRX
LUCD

About OPRX OptimizeRx Corporation

OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.

About LUCD Lucid Diagnostics Inc.

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

Share on Social Networks: